Back to Journals » ClinicoEconomics and Outcomes Research » Volume 1

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab

Authors Patti F, Pappalardo A

Published 21 August 2009 Volume 2009:1 Pages 45—51


Review by Single-blind

Peer reviewer comments 3

Francesco Patti, Angelo Pappalardo

Multiple Sclerosis Center, University of Catania, Catania, Italy; Physical Medicine and Rehabilitation Unit, Hospital of Acireale, Catania, Italy

Abstract: Multiple sclerosis is a frequent neurologic disease, which causes sensory impairment, fatigue, cognitive deficits, imbalance, loss of mobility, spasticity, and bladder and bowel dysfunction. Several new therapies have been introduced in the past decade, but additional drugs are needed to slow disease progression and reduce disability. Natalizumab (NA) is an α4 integrin antagonist, effective in decreasing the development of brain lesions in experimental models and in several studies of patients with MS. Six randomized controlled trials of NA in MS have been published in the last 10 years. Overall, 2,688 relapsing-remitting MS subjects have been enrolled in these studies. Hence, there are already sufficient data to draw some conclusions about the effectiveness of NA in the treatment of MS, although for definitive considerations it would be reasonable to wait for the observational phase IV studies of clinical practice to complete. Moreover, the medical community is concerned with the safety of NA, particularly with the risk of developing progressive multifocal leukoencephalopathy while on NA therapy. From the analyses of the six cases, it seems that the overall risk is around 1/1,000 and could increase with the number of NA infusions.

Keywords: multiple sclerosis, disease-modifying drugs, natalizumab, progressive multifocal leukoencephalopathy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Current perspectives in stem cell research for knee cartilage repair

Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucchiarini M

Stem Cells and Cloning: Advances and Applications 2014, 7:1-17

Published Date: 16 January 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Biomarkers for osteoarthritis: investigation, identification, and prognosis

Zhai G, Aref Eshghi E

Current Biomarker Findings 2012, 2:19-28

Published Date: 29 June 2012

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011